RARE Annual Total Long Term Liabilities
$935.16 M
+$3.42 M+0.37%
31 December 2023
Summary:
As of January 23, 2025, RARE annual total long term liabilities is $935.16 million, with the most recent change of +$3.42 million (+0.37%) on December 31, 2023. During the last 3 years, it has risen by +$519.59 million (+125.03%). RARE annual total long term liabilities is now at all-time high.RARE Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE Quarterly Long Term Liabilities
$899.53 M
-$13.63 M-1.49%
30 September 2024
Summary:
As of January 23, 2025, RARE quarterly total long term liabilities is $899.53 million, with the most recent change of -$13.63 million (-1.49%) on September 30, 2024. Over the past year, it has dropped by -$52.92 million (-5.56%). RARE quarterly long term liabilities is now -5.56% below its all-time high of $952.45 million, reached on September 30, 2023.RARE Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RARE Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.4% | -5.6% |
| 3 y3 years | +125.0% | +116.7% |
| 5 y5 years | +2503.1% | +1342.2% |
RARE Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +123.5% | -5.6% | +115.0% |
| 5 y | 5-year | at high | +147.1% | -5.6% | +137.7% |
| alltime | all time | at high | >+9999.0% | -5.6% | >+9999.0% |
Ultragenyx Pharmaceutical Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $899.53 M(-1.5%) |
| June 2024 | - | $913.15 M(-0.9%) |
| Mar 2024 | - | $921.24 M(-1.5%) |
| Dec 2023 | $935.16 M(+0.4%) | $935.16 M(-1.8%) |
| Sept 2023 | - | $952.45 M(+1.6%) |
| June 2023 | - | $937.90 M(-0.7%) |
| Mar 2023 | - | $944.74 M(+1.4%) |
| Dec 2022 | $931.74 M(+122.7%) | $931.74 M(+1.0%) |
| Sept 2022 | - | $922.28 M(+118.6%) |
| June 2022 | - | $421.92 M(+0.4%) |
| Mar 2022 | - | $420.37 M(+0.5%) |
| Dec 2021 | $418.47 M(+0.7%) | $418.47 M(+0.8%) |
| Sept 2021 | - | $415.19 M(+0.5%) |
| June 2021 | - | $413.21 M(-0.7%) |
| Mar 2021 | - | $416.14 M(+0.1%) |
| Dec 2020 | $415.57 M(+9.8%) | $415.57 M(+3.6%) |
| Sept 2020 | - | $401.01 M(+0.6%) |
| June 2020 | - | $398.73 M(-6.7%) |
| Mar 2020 | - | $427.14 M(+12.9%) |
| Dec 2019 | $378.43 M(+953.4%) | $378.43 M(+506.7%) |
| Sept 2019 | - | $62.37 M(-2.7%) |
| June 2019 | - | $64.13 M(+18.4%) |
| Mar 2019 | - | $54.15 M(+50.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $35.92 M(-1.0%) | $35.92 M(+0.2%) |
| Sept 2018 | - | $35.87 M(-0.4%) |
| June 2018 | - | $36.00 M(-0.3%) |
| Mar 2018 | - | $36.11 M(-0.5%) |
| Dec 2017 | $36.28 M(+467.6%) | $36.28 M(+594.1%) |
| Sept 2017 | - | $5.23 M(-3.4%) |
| June 2017 | - | $5.41 M(-3.1%) |
| Mar 2017 | - | $5.59 M(-12.6%) |
| Dec 2016 | $6.39 M(+1039.6%) | $6.39 M(-27.7%) |
| Sept 2016 | - | $8.85 M(+45.6%) |
| June 2016 | - | $6.07 M(+35.6%) |
| Mar 2016 | - | $4.48 M(+698.6%) |
| Dec 2015 | $561.00 K(+11.1%) | $561.00 K(-11.5%) |
| Sept 2015 | - | $634.00 K(-7.3%) |
| June 2015 | - | $684.00 K(+43.1%) |
| Mar 2015 | - | $478.00 K(-5.3%) |
| Dec 2014 | $505.00 K(-86.0%) | $505.00 K(-5.3%) |
| Sept 2014 | - | $533.00 K(-4.8%) |
| June 2014 | - | $560.00 K(+207.7%) |
| Mar 2014 | - | $182.00 K(-95.0%) |
| Dec 2013 | $3.62 M(+359.3%) | $3.62 M(+97.8%) |
| Sept 2013 | - | $1.83 M(+132.2%) |
| Dec 2012 | $788.00 K(+61.8%) | $788.00 K |
| Dec 2011 | $487.00 K | - |
FAQ
- What is Ultragenyx Pharmaceutical annual total long term liabilities?
- What is the all time high annual total long term liabilities for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual total long term liabilities year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly long term liabilities year-on-year change?
What is Ultragenyx Pharmaceutical annual total long term liabilities?
The current annual total long term liabilities of RARE is $935.16 M
What is the all time high annual total long term liabilities for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual total long term liabilities is $935.16 M
What is Ultragenyx Pharmaceutical annual total long term liabilities year-on-year change?
Over the past year, RARE annual total long term liabilities has changed by +$3.42 M (+0.37%)
What is Ultragenyx Pharmaceutical quarterly total long term liabilities?
The current quarterly long term liabilities of RARE is $899.53 M
What is the all time high quarterly long term liabilities for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly total long term liabilities is $952.45 M
What is Ultragenyx Pharmaceutical quarterly long term liabilities year-on-year change?
Over the past year, RARE quarterly total long term liabilities has changed by -$52.92 M (-5.56%)